![[제약계 소식] January 19-Doctor’s newspaper](http://www.doctorstimes.com/news/thumbnail/202101/213764_52159_5514_v150.jpg "[제약계 소식] January 19-Doctor’s newspaper")
■Hyundai Pharm, presents non-face-to-face paid classical performances
Hyundai Pharm’s Social Contribution Activities Art M Concert has successfully completed the one-time performance of’Art M Untitled Studio’, an online non-face-to-face concert that has been newly introduced from this year, and has started in earnest to revitalize online paid classical performances.
Art M Untitled Studio is a non-face-to-face classical performance that provides an online performance platform to the performance industry and performers, which have been difficult due to the corona, and is held through Naver TV’s’Sponsored Live’.
It is meaningful in that it is a’non-face-to-face interactive classical performance’ that provides a venue for performances to performers who yearn for the stage, and provides services for viewers to enjoy performances comfortably at a relatively reasonable cost and even communicate directly with the performers. have.
The first stage was decorated by’Club M-var.1′ composed of violinist Kim Deok-woo, violist Lee Shin-kyu, cellist Shim Jun-ho, and pianist Kim Jae-won. The performance was carried out while fully showing the strengths that could be made.
In particular, this performance gained great response with the cumulative number of audiences exceeding 2000, and pioneered the field of classical performance among the live sponsored by Naver TV.
An official from Hyundai Pharm said, “Art M Untitled Studio is the first challenge as an alternative paid online classical concert in the performing industry where it is difficult to present an offline stage.” “Starting with this one-time performance, Art M Untitled Studio will become a new classical performance culture. We will lay the groundwork and develop it so that we can establish ourselves.”
■Woorideul Pharmaceutical opens its own export path for 3 types of corona diagnostic kits with CE certification
Wooridul Pharmaceutical Co., Ltd. (CEO Kim Hye-yeon, Park Hee-deok) announced on the 19th that it has successfully acquired European CE certification for three corona 19 diagnostic kits as of January 8.
The diagnostic kits that obtained this certification are two types of molecular diagnosis (PCR) methods (‘fineGENE™ N-CoV RT-PCR’ and’fineGENE™ COVID-19 RT-PCR’) and one rapid antigen diagnosis kit (‘findUS ™ COVID-19 antigen’). In addition, Wooridul Pharmaceutical announced that it is undergoing the CE certification process for one type of antibody diagnosis rapid kit (‘findUS™ COVID-19 IgM/IgG’).
In November last year, Wooridul Pharmaceutical acquired ISO 13485 certification, an international standard medical device quality management system, in order to secure international public confidence in the manufacturing and sales of in vitro diagnostic medical devices (on-site diagnostic testing products).
The three diagnostic kits that succeeded in CE certification this time were developed through technical cooperation with Access Bio, a US-based subsidiary, acquired by Wooridul Pharmaceutical in 2019. Accessbio obtained CE and US FDA emergency approval for molecular diagnosis method, antigen and antibody diagnosis method rapid kit last year.
Corona 19 diagnostic kit is largely divided into a molecular diagnostic method, an RT-PCR diagnostic kit, an immunological method, an antibody, and a rapid antigen diagnosis kit. Molecular diagnosis is useful for early diagnosis of infection, but it takes a long time to test, and the rapid antibody diagnosis kit provides high accuracy and rapid diagnosis at the end of the infection.
For that reason, the need for a combination of molecular diagnosis and antibody diagnosis rapid kits is increasing. In addition, the rapid antigen diagnosis kit can determine whether the diagnosis is confirmed within 10 to 15 minutes, even for early patients who were difficult to diagnose with the existing antibody diagnosis rapid kit.
Wooridul Pharmaceutical said, “We expect to complete the certification of the remaining antibody diagnosis rapid kits as well as the European CE certification soon.” “We will focus our efforts on activating overseas business using the four corona 19 diagnostic kits as a cornerstone.”
■Dongwha Pharm launches’Komakiten Nasal Spray’, a treatment for rhinitis
Dong Wha Pharm announced on the 18th that it has launched’Komakiten Nazal Spray’, a rhinitis treatment that is rooted by Donghwa Pharmaceutical.
Komakiten Nazal Spray helps relieve symptoms of nasal cold (acute rhinitis), allergic rhinitis, stuffy nose, runny nose, sneezing, and heaviness in head. Nasal Spray is an administration method in which drugs are directly injected into the nasal cavity, and has the advantage of maintaining a high concentration of drugs and minimizing systemic side effects.
The main ingredient, xylometazoline hydrochloride, is a nasal decongestant that quickly enlarges the nasal cavity and maintains the effect of improving nasal congestion for up to 12 hours. In addition, the antihistamine action of chlorpheniramine maleate relieves symptoms such as sneezing and runny nose. As an additive, it contains phytoncide scent and contains sodium hyaluronate, which improves wettability, so it improves dryness in the nose caused by xylometazoline hydrochloride, a nasal decongestant.
The product container uses a special pump from Aptar, Germany, and the amount of spray sprayed is constant compared to the existing pump. When not in use, the nozzle part is kept closed, and one way air flow air filter technology is applied so that germs do not penetrate, so it can be used hygienically.
An official of Dong Wha Pharm said, “There are many people who suffer from rhinitis or a cold, especially during the dry winter months when the temperature is low. Komakiten Nasal Spray is a product that reflects the needs of consumers and compensates for the dryness in the nose and the discomfort of using a container while using the existing spray-type rhinitis treatment. It is expected that it will improve the stuffy symptoms such as stuffy nose and runny nose faster and more conveniently.”
Dong Wha Pharm’s Komakiten Nasal Spray is a 20ml dose and can be purchased at a pharmacy as an over-the-counter drug. To use, hold the product with the hand on the opposite side of the nose to be sprayed once a day, once a day to a child or adult over 7 years old, put the nozzle outward from the center of the nose, and spray the drug.
Dongsung Pharmaceutical donates medicines to Gangwon-do to overcome COVID-19
Dongsung Pharmaceutical (CEO Yang-gu Lee) held a delivery ceremony for medicines and probiotics lactobacillus to overcome Corona 19 and support health care for vulnerable groups on January 15 at the Commerce Consultation Office of Gangwon Provincial Office.
With the prolonged spread of Corona 19, everyone is having a difficult and difficult time. Accordingly, Dongsung Pharmaceutical is in Gangwon-do to support Gangwon-do medical centers and public medical institutions, which are designated and operated as infectious diseases exclusive hospitals for the treatment of corona patients, and to help the health management of the elderly and vulnerable people who need essential medical services in Gangwon-do. They donated 50 million won worth of medicines and probiotics.
The delivered medicine is’Cramax tablet’, a penicillin antibiotic that treats various infections caused by bacteria. The probiotic lactobacillus’Biogaia Gastrus’ delivered together helps manage intestinal health and immunity, especially in relieving side effects such as diarrhea and vomiting that occur when taking antibiotics.
The sponsored goods will be appropriately delivered to the vulnerable in 5 Gangwon Medical Centers and 18 cities and counties located in Gangwon-do, and will be used to improve the medical welfare of local residents.
Lee Yang-gu, CEO of Dongsung Pharmaceutical, said, “I hope this sponsorship product will be of little help to local residents who are having a hard time with Corona 19. I hope that everyone will work together to overcome the difficult situation.” Told. (End)
■Yoo Health Care, Received a Presidential Citation for Job Creation
Yuyu Healthcare, a subsidiary of Yuyu Pharmaceutical, was awarded a presidential citation in recognition of its contribution to the development of the national industry through job creation support.
YooYu Healthcare recorded 86 workers, a 48.2% increase in the number of workers compared to the previous year (as of 2020), of which the youth employment growth rate increased by 26% from 23 to 29. In addition, the employment retention rate (employment stability) for the last one year was 84.4%, and the proportion of regular workers among the workers employed in the last one year recorded 64.8%. In particular, by creating a good working environment for women to work, the ratio of female recruitment was 64.7%, and older workers (55 years of age or older) also maintain continuous employment.
Last year, Yuyu Healthcare expanded a new factory with a construction area of 4,950m2 on a 17,922m2 site in Hoengseong Woocheon, Gangwon-do, and is continuing to establish plans to hire new personnel.
Yoo Health Care was recognized for its contribution to job creation and job security in Gangwon-do, and won the excellence award at the 2nd Gangwon Job Awards. It was also selected as a company.
■Bukwang Pharm’s anticancer drug SOL-804 registered patents in Europe, etc.
Bukwang Pharm announced that the patent for the composition of the anticancer drug SOL-804 of its subsidiary Dynacerapeutics was registered in Europe, Eurasia, Australia, and Mexico following Japan. Currently, the IND for phase 1 clinical trials to be conducted in Korea is submitted and awaiting approval, and after the Korean clinical trial, the clinical trial will be conducted in Europe.
SOL-804 is an improved new drug that improves the existing treatment for metastatic castration-resistant prostate cancer, and is a product developed exclusively by Dynatherapeutics after obtaining worldwide development and copyright from Solural Pharma (Solural Pharma), Denmark in 2016.
It is possible to avoid the effect of food, which is a problem with existing treatments, so that the patient’s convenience in taking and medication compliance can be increased, and development of these uses is expected to result in rapid development as there are cases where approval and sales are possible only with the results of phase 1 clinical trials Are doing.
The technology applied by Dynacerapeutics to SOL-804 is a drug delivery platform technology, and is expected to be widely applied to various anticancer drugs in the future to produce an effect with a small dose and reduce side effects. Dyna Therapeutics is a wholly-owned subsidiary of Bukwang Pharmaceutical, which specializes in the development of new formulations for pharmaceuticals.
Bukwang Pharm and Dyna Therapeutics said, “The patent for SOL-804 has been registered in Europe, and it is expected to show relatively rapid results by proving that it is not affected by food and improves the absorption rate of existing treatments through phase 1 tests in Korea and Europe. I can see it.”
Bukwang Pharm is conducting clinical trials for antiviral drugs for COVID-19 and schizophrenia treatments. It is expected to conduct clinical trials for prostate cancer treatment. In addition, through a joint venture Jaguar in Singapore, immuno-cancer drugs and Parkinson’s disease treatments are being developed with Oxford-Dundy University in the UK, and various new drugs are being developed, focusing on the CNS and anti-cancer drugs fields.
Copyright owner © Doctor Shinmun Unauthorized reproduction and redistribution prohibited